+1-888-308-5802      . .

Rune Labs & BlueRock collaborate for research on Parkinson’s disease

Author : Pankaj Singh | Published Date : 2023-03-17 

Rune Labs & BlueRock collaborate for research on Parkinson’s disease

Rune Labs, a neurology software and data platform provider, has recently announced a collaboration with biopharmaceutical firm BlueRock Therapeutics, a wholly owned subsidiary of Bayer AG. BlueRock will use the clinical trial technology of Rune Labs featuring patient monitoring and data collection facilities, named StriveStudy, to delve into the root cause of the Parkinson’s disease.

This is the first partnership of both companies with each other and is also the first deployment of the StriveStudy clinical trial platform, in order to facilitate better research of therapeutics to treat movement disorders. Rune Labs’ technology will be used by BlueRock in a non-interventional study to capture Parkinson’s symptoms data through Apple Watch-enabled tools for data collection and remote patient monitoring.

The CEO of Rune Labs, Brian Pepin, has shared that the research on Parkinson’s disease has been limited in the past, since people who suffer from the disorder display varying sets of symptoms. Furthermore, subjective tools commonly used by researchers, such as patient-reported questionnaires, are unable to capture the dynamic nature of the disease, he added. Through this collaboration, claims Pepin, the companies will work on establishing a baseline dataset for symptoms of Parkinson’s disease to fully derive benefits from advanced therapies and increase the efficiency of future clinical trials.

According to President and CEO of BlueRock Therapeutics, Seth Ettenberg, the firm is looking forward to partnering with Rune Labs to drive progress in the development of medical therapy for diseases such as Parkinson’s.

Rune Labs is also providing a first-hand chance to conduct trials for and streamline BlueRock’s stem cell-based therapy bemdaneprocel technology. Through StriveStudy, BlueRock will be able to conduct subsequent data analysis on baseline and follow-up data, including dyskinesias, to gain a more comprehensive understanding of the therapeutic advantages of the first-in-class therapy.

For the record, RuneLabs is a data analytics company that is involved in precision neurology therapy development.  The firm has financial help from various investors like Eclipse Ventures, DigiTx, and Moment Ventures, among others.

Source Credit: https://www.prnewswire.com/news-releases/bluerock-therapeutics-to-use-rune-labs-clinical-trial-platform-to-better-characterize-parkinsons-disease-state-in-cell-therapy-trials-301771114.html

About Author

Pankaj Singh . .

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

JPMorgan revises India’s 2024 growth outlook fueled by higher Q1 GDP

JPMorgan revises India’s 2024 growth outlook fueled by higher Q1 GDP

Published Date: 2023-06-02         Author: Pankaj Singh

JPMorgan & Co., the American financial services company, has reportedly increased its economic forecast 2024 for India. It also recommended caution due to a global slowdown. The investment bank raised its growth estimation from 5% to 5.5%, taking into account the latest data showing India'... Read More>>

Ola Electric-Kotak collaborate for IPO structure to debut in early 2024

Ola Electric-Kotak collaborate for IPO structure to debut in early 2024

Published Date: 2023-05-26         Author: Pankaj Singh

Ola Electric, an electric mobility startup, has reportedly showcased interest in investment banks Goldman Sachs and Kotak Mahindra Capital to assist with the upcoming IPO in early 2024. The company aims to go public before the discontinuation of government subsidies for electric vehicles. This mo... Read More>>

Tianqi Lithium foresees more M&As in Lithium sector in near future

Tianqi Lithium foresees more M&As in Lithium sector in near future

Published Date: 2023-05-19         Author: Pankaj Singh

Tianqi Lithium (002466.SZ), a China-based major lithium producers, has reportedly cited the anticipation for more consolidation in the lithium industry. The reckoning comes after the recent merger worth $10.6 billion between Allkem Ltd. and Livent Corp. The deal has showcased a possibility for more ... Read More>>

© 2023 Fractovia. All Rights Reserved